Hepatocellular Carcinoma Cell Models for Research

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for approximately 75-85% of cases. According to the World Health Organization (WHO), liver cancer was the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide in 2020, with an estimated 905,677 new cases and 830,180 deaths. The incidence is highest in East Asia and sub-Saharan Africa, but it has been rising in Western countries due to non-alcoholic fatty liver disease (NAFLD). Major risk factors include chronic hepatitis B or C infection, aflatoxin exposure, alcohol abuse, and metabolic syndrome. The prognosis remains poor, with a 5-year survival rate of about 20% for localized disease and less than 5% for distant metastasis, according to the National Cancer Institute (NCI) SEER data. Early-stage HCC can be treated with resection, ablation, or transplantation, but most patients present with advanced disease, underscoring the need for novel therapeutic strategies.

HCC is an ideal model for mechanistic studies due to its well-characterized molecular subtypes, extensive public datasets, and the availability of numerous cell lines. The Cancer Genome Atlas (TCGA) has profiled over 370 HCC tumors, revealing frequent mutations in TERT promoter, TP53, CTNNB1, and other genes. These data provide a foundation for functional genomics studies. Open questions include the role of tumor heterogeneity, the interplay between genetic alterations and the tumor microenvironment, and the mechanisms of drug resistance. Gene-edited cell models are essential for dissecting these pathways and validating novel therapeutic targets.

Several pathways are frequently deregulated in HCC:

1. Wnt/β-catenin pathway: Activation of CTNNB1 (β-catenin) or inactivation of APC or AXIN1 leads to nuclear accumulation of β-catenin and transcriptional activation of target genes (e.g., MYC, CCND1). This occurs in about 30-40% of HCCs.

2. p53 pathway: TP53 mutations are present in ~30% of HCCs, leading to loss of tumor suppressor function and genomic instability. Mutant p53 can also gain oncogenic functions.

3. PI3K/AKT/mTOR pathway: Activation via PIK3CA mutations, PTEN loss, or amplification of AKT1 promotes cell survival and proliferation.

4. RAS/MAPK pathway: Mutations in KRAS, NRAS, or BRAF are less common but can activate the pathway, leading to uncontrolled growth.

Data from TCGA and COSMIC.

Key signaling networks in HCC include:

• • Wnt/β-catenin: CTNNB1, APC, AXIN1, GSK3B, TCF/LEF transcription factors.
• • p53: TP53, MDM2, ATM, CHEK2.
• • PI3K/AKT/mTOR: PIK3CA, PTEN, AKT1, MTOR, RICTOR.
• • RAS/MAPK: KRAS, NRAS, BRAF, RAF1, MEK1/2, ERK1/2.
• • Growth factor signaling: EGFR, IGF1R, MET, VEGFR.
• • Cell cycle: CDKN2A, RB1, CCND1, CDK4/6.

These networks cross-talk and contribute to tumor initiation, progression, and metastasis.

Common HCC cell lines include:

Organoids derived from patient tumors preserve heterogeneity and 3D architecture, making them valuable for drug testing and personalized medicine.

Animal models for HCC include:

• • Patient-derived xenografts (PDX): Tumor fragments implanted into immunodeficient mice, preserving patient tumor features.
• • Genetically engineered mouse models (GEMM): e.g., Alb-Cre;Trp53fl/fl, MUP-uPA;CTNNB1S45Y, or hydrodynamic tail vein injection of transposons carrying oncogenes.
• • Chemical-induced models: Diethylnitrosamine (DEN), carbon tetrachloride (CCl4) in mice or rats.
• • Orthotopic models: Injection of HCC cells into the liver of mice for metastatic studies.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as knockouts (KO) of tumor suppressors or knock-ins (KI) of oncogenic mutations. These models are invaluable for studying gene function and drug response. For example:

• • TP53 knockout cell lines: Generated in HepG2 or Huh-7 to study loss of p53 function.
• • CTNNB1 knock-in cell lines: Introduction of activating mutations (e.g., S33Y) into wild-type cells to model Wnt activation.
• • TERT promoter mutant lines: Knock-in of promoter mutations to study telomerase reactivation.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing consistent and validated models, but specific company names are not mentioned here.

Gene-edited cells are used to validate the functional significance of genetic alterations. For example:

• • Knockout of tumor suppressors (e.g., TP53, PTEN) to assess effects on proliferation, apoptosis, and migration.
• • Knock-in of oncogenic mutations (e.g., CTNNB1 S33Y) to study pathway activation and downstream effects.
• • CRISPR screens with pooled sgRNA libraries to identify genes essential for HCC cell survival or resistance to drugs.

Isogenic pairs (wild-type vs. gene-edited) are powerful for drug screening. For example:

• • TP53 KO cells can be used to test p53-dependent drug responses.
• • CTNNB1 mutant cells can be used to screen for Wnt pathway inhibitors.
• • Resistance modeling: Chronic exposure of gene-edited cells to drugs can select for resistant clones, revealing mechanisms of acquired resistance.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, are lethal only in the context of a specific mutation. For example:

• • In TP53-mutant HCC, screening for genes essential for survival can reveal novel therapeutic targets.
• • Gene-edited cells can also be used to identify biomarkers of drug sensitivity or resistance by correlating genetic status with response.